Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions
Completed · Early Phase 1
Conditions studied: Dry Mouth
In brief
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fed conditions
Key facts
- Study ID
- NCT01903109
- Run by
- Roxane Laboratories
- People needed
- 27
- Starts
- 2009-02-01
- Expected to finish
- 2009-02-01
- Last updated by the study team
- 2018-01-23
Who can join
Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening
You may not qualify if…
- Positive test for HIV, Hepatitis B, or Hepatitis C.
- Treatment with known enzyme altering drugs.
- History of allergic or adverse response to cevimeline or any comparable or similar product.
Where it is running
- Novum Pharmaceutical Research Services — Las Vegas, Nevada, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.